About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More


A Phase III Trial of Niraparib Versus Physician's Choice in Her2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

Note: This study is also known as the BRAVO StudyBRAVO logo

Study identifier: NCT01905592
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Niraparib (Tesaro)


Inclusion Criteria

  • Germline BRCA1 or BRCA2 mutation; patients with unknown BRCA status who meet NCCN BRCA screening criteria will be screened for BRCA mutation.
  • Metastatic or locally advanced disease that is not amenable to resection or radiation with curative intent.
  • Up to 2 prior cytotoxic regimens for advanced or metastatic breast cancer
    • patients with no prior cytotoxic regimens for advanced or metastatic disease will only be allowed if they relapsed during or within 12 months of (neo-) adjuvant cytotoxic therapy that included a taxane and anthracycline, if not contraindicated.
    • Prior therapy should have included an anthracycline and a taxane (or contraindication to those) in the neoadjuvant, adjuvant, or advanced/metastatic setting. a.
  • Hormone receptor positive patients must also have hormone resistant disease (progression during at least one prior hormonal therapy) for which chemotherapy is indicated.
    ECOG performance status 0-2
  • Adequate bone marrow, kidney and liver function

Exclusion Criteria

  • Must not have received any prior PARP inhibitor therapy
  • Patients with platinum resistant cancer
  • Symptomatic uncontrolled brain metastasis
  • Prior diagnosis of Stage IV ovarian cancer; Stage III ovarian cancer must have a 5-year disease-free interval and normal CA125; Stage II ovarian cancer must have a 2-year disease-free interval and normal CA125
  • Invasive cancer other than ovarian cancer within 2 years (except basal or squamous cell carcinoma of the skin that has been definitely treated)

Type of study:

Randomized Phase III


  • Patients will be randomized to one of two arms:
    • Patients will be randomized 2:1 to receive niraparib 3 oral capsules (100mg) once daily for 21 continuous days or physicians choice of 4 standard of care metastatic breast cancer chemotherapies

Study sites:

Study sites:

Contact study coordinators below where listed. For more information about BRAVO and all open sites contact:

Shefali Agarwal, MD: 781-916-837or sagarwal@tesarobio.com or
Beth Zaharoff: bzaharoff@tesarobio.com

City of Hope
Principal Investigator is Dr. George Somlo
Study Coordinator: Kim Robinson krobinson@coh.org or (626) 256-4673

Ft. Myers
Florida Cancer Specialists & Research Institute-
Principal Investigator: Dr. Lowell Hart
Primary Study Coordinator: Cara O’Keefe cokeefe@flcancer.com or 239-274-9930

Florida Cancer Institute
Principal Investigator: Dr. Gail Wright
Primary Study Coordinator: Christine Biermeier cbiermeier@flcancer.com or 727-216-1143

New Mexico
San Juan Regional Cancer Center - San Juan Oncology Association
Principal Investigator: Dr. Jeffrey Neidhart
Study Coordinator: Jessica Barnes at jessica@sjonc.com or 505-564-6850

Tennessee Oncology
Principal Investigator: Dr. Denise Yardley
Study Coordinator: Ellen Crabtree: Ellen.Crabtree@scresearch.net or 615- 524-4360

San Antonio
Cancer Care Centers of South Texas
Principal Investigator: Dr. Sharon Wilks.
Primary Study Coordinator: Theodora Coutinho:
or (210) 424-2610

Providence Regional Medical Center
Principal Investigator: Dr. Elie Saikaly
Primary Study Coordinator: Katie Lyon Katie.lyon@providence.org or 425-297-5531

Page updated 03/05/14

Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us


This site has been made possible by a generous grant from Morphotek.

Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org